You are here

Resize Text
See all clinical trials

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative

RETHINC is a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily in symptomatic current and former smokers with respiratory symptoms despite preserved spirometry as defined by CAT ≥ 10 and post-bronchodilator FEV1/FVC ratio ≥0.70, respectively.

Clinical Trial Information

Protocol
IRB#24255, WIRB#:20170354
Phase
3
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Investigator
Gerard J Criner, MD
Coordinator
Dolores Fehrle, RN

Visit clinicaltrials.gov for full clinical trial description.

Contact

For more information about this trial or to inquire about eligibility, email breathe@temple.edu

Full Title

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative